Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HIVAC-1e

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1999
Review
1999
Bristol-Myers Squibb is developing a vaccine, HIVAC-1e, comprised of a recombinant vaccinia virus expressing the HIV-1 gp160… Expand
Is this relevant?
1995
1995
Cytotoxic T lymphocytes (CTL) play an important role in the immune response to viral infection by recognizing and destroying… Expand
Is this relevant?
1994
1994
Priming with a live recombinant vector followed by subunit boosting is a promising strategy for human immunodeficiency virus (HIV… Expand
Is this relevant?
1993
1993
Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers… Expand
Is this relevant?
1992
1992
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) gp160 recombinant vaccinia virus (HIVAC-1e… Expand
Is this relevant?
Highly Cited
1991
Highly Cited
1991
In a randomised phase I trial of a recombinant vaccina virus vaccine expressing the gp160 envelope gene of the human… Expand
Is this relevant?